MCID: CLR109
MIFTS: 54

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 15 17
Adenocarcinoma of Large Intestine 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
UMLS 74 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to adenocarcinoma and colorectal adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Iron and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.2 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
2 colorectal adenoma 31.1 CTNNB1 HRAS KRAS MLH1 MSH2 TP53
3 gastrointestinal stromal tumor 30.6 BRAF EGFR KRAS TP53
4 renal cell carcinoma, nonpapillary 30.2 CDH1 EGFR KRT20 KRT7
5 chordoma 30.2 CDH1 EGFR KRT7
6 villous adenoma 30.1 BRAF CDX2 KRAS KRT20
7 mucinous bronchioloalveolar adenocarcinoma 30.0 CDX2 KRT20 KRT7
8 adenoma 29.8 BRAF CTNNB1 KRAS MLH1 MSH2 TP53
9 mucinous adenocarcinoma 29.6 CDX2 EGFR KRAS KRT20 KRT7 MLH1
10 lynch syndrome 29.6 BRAF CTNNB1 EGFR KRAS MLH1 MSH2
11 bladder adenocarcinoma 29.5 CDX2 CTNNB1 HRAS KRT20 KRT7
12 familial adenomatous polyposis 29.4 CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
13 squamous cell carcinoma 29.4 BRAF CDH1 CTNNB1 EGFR HRAS TP53
14 intrahepatic cholangiocarcinoma 29.0 CDH1 CDX2 CTNNB1 EGFR KRAS KRT20
15 hepatocellular carcinoma 28.8 CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
16 esophageal cancer 28.7 CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
17 cholangiocarcinoma 28.6 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
18 lung cancer 28.5 BRAF CDH1 CEACAM5 EGFR HRAS KRAS
19 lung cancer susceptibility 3 28.2 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
20 gastric adenocarcinoma 28.0 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
21 intestinal disease 28.0 CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
22 colorectal cancer 27.9 AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
23 bladder squamous cell carcinoma 10.6 BRAF TP53
24 nevus of ota 10.6 BRAF TP53
25 rare adenocarcinoma of the breast 10.6 KRAS TP53
26 vulvar intraepithelial neoplasia 10.5 KRT7 TP53
27 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
28 transverse colon cancer 10.5 KRT20 KRT7
29 colloid adenoma 10.5 KRT20 TP53
30 papillary transitional carcinoma 10.5 KRT20 KRT7
31 cystic basal cell carcinoma 10.5 KRT20 KRT7
32 malignant syringoma 10.5 KRT20 KRT7
33 eyelid carcinoma 10.5 KRT20 KRT7
34 krukenberg carcinoma 10.5 KRT20 KRT7
35 small cell carcinoma of the bladder 10.5 KRT20 KRT7
36 ovary neuroendocrine neoplasm 10.5 CDX2 KRT7
37 vaginal benign neoplasm 10.5 CDX2 KRT20
38 vaginal adenoma 10.5 CDX2 KRT20
39 vaginal tubulovillous adenoma 10.5 CDX2 KRT20
40 cerebral convexity meningioma 10.5 CDH1 TP53
41 renal pelvis adenocarcinoma 10.5 CDH1 KRT7
42 benign breast adenomyoepithelioma 10.5 EGFR KRT7
43 brain ependymoma 10.5 EGFR TP53
44 oncocytic breast carcinoma 10.5 EGFR KRT7
45 intracranial chondrosarcoma 10.5 CEACAM5 TP53
46 cutaneous mucoepidermoid carcinoma 10.5 CEACAM5 KRT7
47 anal gland adenocarcinoma 10.5 CEACAM5 KRT7
48 anal paget's disease 10.5 CDX2 CEACAM5
49 adult hepatocellular carcinoma 10.4 CTNNB1 TP53
50 ovarian clear cell carcinoma 10.4 KRAS KRT7 TP53

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

27 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.92 AURKA EGFR HRAS KRAS PIM2 BRAF
2 Decreased viability GR00106-A-0 10.92 KRAS
3 Decreased viability GR00173-A 10.92 CDK8
4 Decreased viability GR00221-A-1 10.92 AURKA CDH1 CDK8 EGFR HRAS KRAS
5 Decreased viability GR00221-A-2 10.92 AURKA CDK8 HRAS KRAS
6 Decreased viability GR00221-A-3 10.92 HRAS
7 Decreased viability GR00221-A-4 10.92 AURKA CDK8 EGFR BRAF
8 Decreased viability GR00231-A 10.92 AURKA
9 Decreased viability GR00301-A 10.92 CDH1 CDK8 KRAS PIM2 BRAF MSH2
10 Decreased viability GR00381-A-1 10.92 KRAS BRAF
11 Decreased viability GR00402-S-2 10.92 AURKA CDH1 CDK8 EGFR HRAS KRAS
12 Decreased cell migration GR00055-A-1 9.97 AURKA BRAF CDK8 CTNNB1 EGFR HRAS
13 Decreased viability in esophageal squamous lineage GR00235-A 9.93 AURKA BRAF CDH1 CDK8 CTNNB1 FABP6
14 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 BRAF CDK8 EGFR
15 Increased cell migration GR00055-A-3 9.43 AURKA BRAF CTNNB1 EGFR HRAS KRAS
16 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AURKA CDK8 EGFR PIM2

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
2 digestive/alimentary MP:0005381 10.25 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
3 homeostasis/metabolism MP:0005376 10.23 BRAF CDH1 CDX2 CTNNB1 EGFR FABP6
4 mortality/aging MP:0010768 10.21 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
5 embryo MP:0005380 10.19 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
6 endocrine/exocrine gland MP:0005379 10.18 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
7 integument MP:0010771 10.09 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
8 craniofacial MP:0005382 10.07 BRAF CTNNB1 EGFR HRAS KRAS SATB2
9 neoplasm MP:0002006 10.06 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
10 limbs/digits/tail MP:0005371 9.95 BRAF CDX2 CTNNB1 EGFR KRAS SATB2
11 no phenotypic analysis MP:0003012 9.8 AURKA CDH1 CTNNB1 EGFR HRAS KRAS
12 pigmentation MP:0001186 9.55 BRAF CTNNB1 EGFR KRAS TP53
13 renal/urinary system MP:0005367 9.5 BRAF CTNNB1 EGFR HRAS KRAS KRT7
14 respiratory system MP:0005388 9.23 BRAF CTNNB1 EGFR HRAS KRAS MLH1

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
2 Hematinics Phase 4,Phase 3,Phase 1,Phase 2
3 Hepcidins Phase 4
4 Ferric Compounds Phase 4
5 Iron Supplement Phase 4
6
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
8
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
10
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
11
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
12
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
13
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
14
Nicotine Approved Phase 3 54-11-5 89594 942
15
Panitumumab Approved, Investigational Phase 3,Phase 2 339177-26-3 50070211
16
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
18
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
19 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
20 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
23 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Antidotes Phase 3,Phase 2,Phase 1
28 Calcium, Dietary Phase 3,Phase 2
29 Protective Agents Phase 3,Phase 2,Phase 1
30 topoisomerase I inhibitors Phase 2, Phase 3,Phase 1
31 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
35 Pharmaceutical Solutions Phase 3,Phase 2
36 Vitamin B Complex Phase 3,Phase 2,Phase 1
37 Trace Elements Phase 3,Phase 2,Phase 1
38 Vitamins Phase 3,Phase 2,Phase 1
39 Folate Phase 3,Phase 2,Phase 1
40 Hormones Phase 3,Phase 2,Phase 1
41 Vitamin B9 Phase 3,Phase 2,Phase 1
42 Nutrients Phase 3,Phase 2,Phase 1
43 Micronutrients Phase 3,Phase 2,Phase 1
44 Endothelial Growth Factors Phase 3,Phase 2
45 Immunoglobulin G Phase 3,Phase 2
46 Mitogens Phase 3,Phase 2,Phase 1
47 Bone Density Conservation Agents Phase 3,Phase 2
48 Tetrahydrofolates Phase 3
49 Formyltetrahydrofolates Phase 3
50 Mitomycins Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
5 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
6 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
7 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9 Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Recruiting NCT02758951 Phase 2, Phase 3
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma Not yet recruiting NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
12 TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases) Not yet recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
13 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
14 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
15 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
16 Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) Unknown status NCT01929616 Phase 2 regorafenib
17 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
18 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
19 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
21 Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Completed NCT02788006 Phase 2 Regorafenib 160 mg
22 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
23 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
24 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
25 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
26 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
27 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
28 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
29 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
30 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
31 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
32 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
33 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
34 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
35 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
36 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
38 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
39 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
40 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41 Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma Recruiting NCT01844076 Phase 1, Phase 2 Phase I (Quinacrine);Capecitabine
42 Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Recruiting NCT03559543 Phase 2
43 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation Recruiting NCT03584711 Phase 2
44 Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases Recruiting NCT03599752 Phase 2 Chemotherapy
45 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
46 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Recruiting NCT03642067 Phase 2 Nivolumab;Relatlimab
47 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting NCT03442569 Phase 2 Panitumumab;Nivolumab;Ipilimumab
48 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2
49 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer Recruiting NCT03475004 Phase 2 Pembrolizumab, Bevacizumab, and Binimetinib
50 A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting NCT02599324 Phase 1, Phase 2 ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

42
Liver, Colon, Lung, Breast, Lymph Node, Appendix, Bone

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 974)
# Title Authors Year
1
Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients. ( 31074597 )
2019
2
Response to "histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by lynch syndrome"-reply. ( 31075301 )
2019
3
Response to "histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by lynch syndrome". ( 31077684 )
2019
4
Cancer in a bang: panel next-generation gene sequencing and OncoScan array analysis of a minute colorectal adenocarcinoma and its precursor adenoma. ( 31087409 )
2019
5
Expression profile of genes associated with the proteins degradation pathways in colorectal adenocarcinoma. ( 31096896 )
2019
6
LETM1 is a potential cancer stem-like cell marker and predicts poor prognosis in colorectal adenocarcinoma. ( 31101574 )
2019
7
LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2. ( 31059049 )
2019
8
Metastatic Colorectal Adenocarcinoma in a Bifid Ureter. ( 30989122 )
2019
9
Id-1 expression in colorectal adenocarcinoma tissues and its clinical significance. ( 30994840 )
2019
10
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? ( 30920041 )
2019
11
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920043 )
2019
12
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920048 )
2019
13
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. ( 30922401 )
2019
14
Tumor-to-Tumor Metastasis of Colorectal Adenocarcinoma to Ovarian Cystadenofibroma: A Case Report and Review of the Literature. ( 30882401 )
2019
15
KRAS mutations in the parental tumour accelerate in vitro growth of tumoroids established from colorectal adenocarcinoma. ( 30884019 )
2019
16
Exposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study. ( 30793813 )
2019
17
The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. ( 30466765 )
2019
18
Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis. ( 30339201 )
2019
19
Identification of LINC01234 and MIR210HG as novel prognostic signature for colorectal adenocarcinoma. ( 30362555 )
2019
20
Hepatobiliary Iminodiacetic Acid Scanning Detects Previously Unknown Hepatic Metastases from Colorectal Adenocarcinoma. ( 30076243 )
2019
21
Correlation study of GAPDH, Bcl-2, and Bax protein immunoexpression in patients with colorectal adenocarcinoma. ( 30581507 )
2018
22
PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. ( 30555542 )
2018
23
Down regulation of lncRNA MEG3 promotes colorectal adenocarcinoma cell proliferation and inhibits the apoptosis by up-regulating TGF-β1 and its downstream sphingosine kinase 1. ( 30556866 )
2018
24
Combined fibrinogen and neutrophil-lymphocyte ratio as a predictive factor in resectable colorectal adenocarcinoma. ( 30568490 )
2018
25
Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. ( 30505575 )
2018
26
Investigation of the Anticancer Mechanism of Isoorientin Isolated from Eremurus Spectabilis Leaves via Cell Cycle Pathways in HT-29 Human Colorectal Adenocarcinoma Cells. ( 30515037 )
2018
27
Isolated bone marrow metastases of colorectal adenocarcinoma. ( 30414232 )
2018
28
Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. ( 30358195 )
2018
29
GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. ( 30321514 )
2018
30
Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. ( 30323980 )
2018
31
The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma. ( 30278464 )
2018
32
Computational analysis of mRNA expression profiles identifies a novel triple-biomarker model as prognostic predictor of stage II and III colorectal adenocarcinoma patients. ( 30214289 )
2018
33
ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. ( 30132516 )
2018
34
Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors. ( 30134852 )
2018
35
Expression of leptin in colorectal adenocarcinoma showed significant different survival patterns associated with tumor size, lymphovascular invasion, distant metastasis, local recurrence, and relapse of disease in the western province of Saudi Arabia. ( 30142858 )
2018
36
Additional lymphadenectomy might not improve survival of patients with resectable metastatic colorectal adenocarcinoma of T4 stage, proximal location, poor/undifferentiation, or N3/N4 stages: a large population-based study. ( 30026839 )
2018
37
SCF/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma. ( 30034943 )
2018
38
Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma. ( 30061254 )
2018
39
Long Noncoding RNAs in Colorectal Adenocarcinoma; an in silico Analysis. ( 29948619 )
2018
40
Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )
2018
41
Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )
2018
42
Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. ( 29955144 )
2018
43
In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )
2018
44
Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: Findings from three large US cohorts. ( 29873077 )
2018
45
SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )
2018
46
Colorectal Adenocarcinoma with an Alternative Serrated Pathway. ( 29805354 )
2018
47
Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. ( 29723603 )
2018
48
Loss of BAP1 Expression Occurs Rarely to Never in Colorectal Adenocarcinoma. ( 28362705 )
2018
49
Clinical and Histopathologic Features of Colorectal Adenocarcinoma in Crohn's Disease. ( 28654553 )
2018
50
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( 28819759 )
2018

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2
Show member pathways
12.98 BRAF CDH1 CDX2 CTNNB1 HRAS KRAS
3 12.78 BRAF EGFR HRAS KRAS TP53
4
Show member pathways
12.7 BRAF EGFR HRAS KRAS TP53
5
Show member pathways
12.7 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
6
Show member pathways
12.69 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7
Show member pathways
12.69 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
8
Show member pathways
12.67 BRAF CDH1 CTNNB1 HRAS KRAS TP53
9
Show member pathways
12.66 BRAF CDH1 EGFR HRAS KRAS TP53
10
Show member pathways
12.6 BRAF EGFR HRAS KRAS TP53
11 12.58 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
12 12.53 AURKA CDK8 MLH1 MSH2 TP53
13
Show member pathways
12.53 CTNNB1 EGFR HRAS KRAS MSH2 TP53
14
Show member pathways
12.52 BRAF EGFR HRAS KRAS TP53
15
Show member pathways
12.46 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16
Show member pathways
12.44 CTNNB1 EGFR HRAS KRAS TP53
17
Show member pathways
12.43 CTNNB1 EGFR HRAS KRAS
18
Show member pathways
12.41 BRAF CTNNB1 HRAS KRAS
19
Show member pathways
12.38 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
20 12.36 CTNNB1 HRAS KRAS TP53
21
Show member pathways
12.29 BRAF FGFBP1 HRAS KRAS
22
Show member pathways
12.27 BRAF HRAS KRAS TP53
23 12.24 BRAF CTNNB1 EGFR HRAS KRAS TP53
24
Show member pathways
12.21 BRAF EGFR HRAS KRAS TP53
25
Show member pathways
12.19 BRAF HRAS KRAS TP53
26
Show member pathways
12.16 BRAF HRAS KRAS TP53
27 12.15 EGFR HRAS KRAS TP53
28 12.12 AURKA BRAF EGFR HRAS KRAS
29
Show member pathways
12.11 BRAF EGFR HRAS KRAS
30 12.09 EGFR MLH1 MSH2 TP53
31
Show member pathways
12.08 EGFR HRAS KRAS TP53
32 12.04 CDH1 CTNNB1 HRAS KRAS
33 12 CTNNB1 HRAS KRAS TP53
34 11.99 CTNNB1 HRAS KRAS TP53
35 11.93 BRAF CTNNB1 EGFR HRAS KRAS TP53
36
Show member pathways
11.87 EGFR HRAS KRAS
37
Show member pathways
11.87 CDH1 CTNNB1 EGFR
38 11.85 EGFR HRAS KRAS
39
Show member pathways
11.81 BRAF HRAS KRAS
40 11.78 BRAF CDH1 CTNNB1 EGFR KRAS MLH1
41 11.76 MLH1 MSH2 TP53
42 11.75 CDH1 CTNNB1 EGFR
43 11.7 HRAS KRAS TP53
44
Show member pathways
11.69 BRAF HRAS KRAS
45 11.66 BRAF CDH1 EGFR HRAS KRAS TP53
46 11.65 BRAF HRAS KRAS
47 11.65 EGFR HRAS KRAS TP53
48 11.62 EGFR HRAS KRAS
49 11.55 HRAS KRAS MLH1 MSH2 TP53
50 11.54 EGFR HRAS KRAS

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 BRAF CTNNB1 HRAS KRAS TP53
2 MAPK cascade GO:0000165 9.88 BRAF EGFR HRAS KRAS
3 cell proliferation GO:0008283 9.88 CTNNB1 EGFR HRAS PIM2 TP53
4 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
5 Ras protein signal transduction GO:0007265 9.74 HRAS KRAS TP53
6 cellular response to drug GO:0035690 9.73 BRAF EGFR TP53
7 positive regulation of cell proliferation GO:0008284 9.73 CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
8 positive regulation of MAP kinase activity GO:0043406 9.69 EGFR HRAS KRAS
9 negative regulation of neuron apoptotic process GO:0043524 9.62 BRAF HRAS KRAS MSH2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 MLH1 MSH2
11 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.58 EGFR TP53
12 entry of bacterium into host cell GO:0035635 9.55 CDH1 CTNNB1
13 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.54 CTNNB1 FGFBP1
14 response to isolation stress GO:0035900 9.49 HRAS KRAS
15 cellular response to indole-3-methanol GO:0071681 9.46 CDH1 CTNNB1
16 positive regulation of isotype switching to IgA isotypes GO:0048298 9.43 MLH1 MSH2
17 negative regulation of cell proliferation GO:0008285 9.43 CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
18 somatic recombination of immunoglobulin gene segments GO:0016447 9.37 MLH1 MSH2
19 negative regulation of apoptotic process GO:0043066 9.17 AURKA BRAF CEACAM5 CTNNB1 EGFR PIM2
20 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.88 AURKA BRAF CDK8 EGFR PIM2
2 ATP binding GO:0005524 9.86 AURKA BRAF CDK8 EGFR MLH1 MSH2
3 protein heterodimerization activity GO:0046982 9.85 AURKA BRAF CTNNB1 EGFR TP53
4 protein kinase binding GO:0019901 9.77 AURKA CTNNB1 EGFR MSH2 TP53
5 protein phosphatase binding GO:0019903 9.58 CTNNB1 EGFR TP53
6 enzyme binding GO:0019899 9.55 CTNNB1 EGFR MLH1 MSH2 TP53
7 mismatched DNA binding GO:0030983 9.43 MLH1 MSH2
8 chromatin binding GO:0003682 9.43 CTNNB1 EGFR MLH1 MSH2 SATB2 TP53
9 guanine/thymine mispair binding GO:0032137 9.32 MLH1 MSH2
10 nucleotide binding GO:0000166 9.1 AURKA BRAF EGFR HRAS KRAS PIM2

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....